Trial
NCT05041101
Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
M.D. Anderson Cancer Center
Collaborators
—
Condition
Breast Inflammatory Carcinoma
Intervention
Eribulin Mesylate
Why stopped
Termination was requested by study supporter IKENA oncology
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-06-13